Floatz Rating
B60/100
Confidence
Indicative
Sponsor
HRYZ Biotech Co.
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
45Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05952947CT.gov HRYZ-T101 Injection for HPV18 Positive Solid Tumor | — | Recruiting | — | — | — |
NCT05787535CT.gov HRYZ-T101 TCR-T Cell for HPV-18 Positive Advanced Solid Tumor | — | Unknown | — | — | — |
NCT02628067CT.gov Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Vulvar Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Cyclophosphamide (this asset) | HRYZ Biotech Co. | P2 | B · 60 |
| Nivolumab | National Cancer Institute (NCI) | P2 | CCC |
| Cilostazol | Emory University | P2 | CCC |
| Durvalumab | M.D. Anderson Cancer Center | P2 | CCC |
| Pembrolizumab | Merck Sharp & Dohme LLC | P2 | CCC |
| Ipilimumab | National Cancer Institute (NCI) | P2 | CCC |
| Dna Plasmid-Encoding Interleukin-12/Hpv Dna Plasmids Therapeutic Vaccine Medi0457 | M.D. Anderson Cancer Center | P2 | CCC |
| Plasmid Encoded Il-12 | M.D. Anderson Cancer Center | P2 | CCC |
| Dehydroepiandrosterone | Ohio State University Comprehensive Cancer Center | P2 | CCC |
+11 more in the Vulvar Carcinoma cohort
Other indications for Cyclophosphamide
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Adult Acute Lymphoblastic Leukemia | — | P4 | BBB · 79 |
| Mycosis Fungoides | — | P4 | BBB · 78 |
| B-Cell Childhood Acute Lymphoblastic Leukemia | — | P3 | BBB · 78 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Cyclophosphamide in Vulvar Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/cyclophosphamide-vulvar-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →